ALZN
Alzamend Neuro, Inc. Common Stock
stockNASDAQ
alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer's disease, bipolar disorder, major depressive disorder ("mdd") and post-traumatic stress disorder ("ptsd"). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat alzheimer's.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.33 | 2026-10-19 | -16.54% | 3.062 |
| 1M | 1.83 | 2026-09-25 | -39.34% | 1.123 |
| 3M | 1.34 | 2026-07-27 | -17.16% | 0.763 |
| 6M | 1.08 | 2026-04-27 | +2.78% | 0.882 |
| 1Y | 2.45 | 2025-10-27 | -54.69% | 1.785 |
| 2Y | 14.49 | 2024-10-25 | -92.34% | — |
| 5Y | 2,875.50 | 2021-10-26 | -99.96% | 1.063 |
Alzamend Neuro, Inc. Common Stock (NASDAQ:ALZN) stock price today is $1.11, and today's volume is 22,113. ALZN is down 1.770% today. The 30 day average volume is 69,043. ALZN market cap is $5.36M with 4.83M shares outstanding.